chr3-37012084-GA-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000249.4(MLH1):c.665del(p.Asn222MetfsTer7) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Consequence
MLH1
NM_000249.4 frameshift
NM_000249.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.02
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-37012084-GA-G is Pathogenic according to our data. Variant chr3-37012084-GA-G is described in ClinVar as [Pathogenic]. Clinvar id is 90307.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr3-37012084-GA-G is described in Lovd as [Pathogenic]. Variant chr3-37012084-GA-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.665del | p.Asn222MetfsTer7 | frameshift_variant | 8/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.665del | p.Asn222MetfsTer7 | frameshift_variant | 8/19 | 1 | NM_000249.4 | ENSP00000231790 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Lynch syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 17, 2015 | This sequence change deletes 1 nucleotide from exon 8 of the MLH1 mRNA (c.665delA), causing a frameshift at codon 222. This creates a premature translational stop signal (p.Asn222Metfs*7) and is expected to result in an absent or disrupted protein product. Truncating variants in MLH1 are known to be pathogenic. This particular truncation has been reported in the literature. This variant has been reported in families affected with Lynch syndrome and Muir-Torre syndrome (PMID: 24344984, 12660027, 10733117). ClinVar contains an entry for this variant (RCV000075797). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Coding sequence variation resulting in a stop codon - |
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 17, 2023 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
Carcinoma of colon Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MLH1 p.Asn222Metfs*7 variant was identified in 4 of 1272 proband chromosomes (frequency: 0.003) from individuals or families with Lynch syndrome (Dominguez-Valentin 2013, Lagerstedt-Robinson 2016). The variant also segregates with the cancer phenotype in HNPCC family (Sarroca 2002). The variant was also identified in dbSNP (ID: rs63751286) as "With Pathogenic allele", ClinVar (classified as pathogenic by Invitae and InSight), and in UMD-LSDB (11x as causal). The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.665del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 222 and leads to a premature stop codon at position 228. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MLH1 gene are an established mechanism of disease in MLH1 associated cancers and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 05, 2022 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 90307). This premature translational stop signal has been observed in individual(s) with Lynch syndrome and Muir-Torre syndrome (PMID: 10733117, 12660027, 24344984). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asn222Metfs*7) in the MLH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 29, 2022 | The c.665delA pathogenic mutation, located in coding exon 8 of the MLH1 gene, results from a deletion of one nucleotide at nucleotide position 665, causing a translational frameshift with a predicted alternate stop codon (p.N222Mfs*7). This mutation has been reported in patients and families affected with Lynch syndrome (Sarroca C et al. Dis. Colon Rectum, 2000 Mar;43:353-60; discussion 360-2; Sarroca C et al. Cancer Genet. Cytogenet., 2003 Apr;142:13-20; Rossi BM et al. BMC Cancer, 2017 Sep;17:623; Dominguez-Valentin M et al. Hered Cancer Clin Pract, 2013 Dec;11:18; Lagerstedt Robinson K et al. J. Natl. Cancer Inst., 2007 Feb;99:291-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at